[Comment] Targeting orexin signalling in narcolepsy

Nearly three decades after the discovery of the orexin (also known as hypocretin) neuropeptides and the identification of orexin deficiency as the cause of narcolepsy type 1,1 orexin 2 receptor (OX2R) agonists could transform care by directly addressing that deficiency. In The Lancet Neurology, Giuseppe Plazzi and colleagues2 report a phase 2 trial of alixorexton (ALKS 2680), an oral OX2R agonist, in narcolepsy type 1.

Läs hela artikeln: Visa original